CereMetrix Corp. was founded in 2016 as a wholly owned subsidiary of CereHealth Corp. with the purpose of providing the most advanced brain-focused imaging and analytics platform for complex neurological and behavioral conditions.
The company received a $250,000 grant in 2017 from the Colorado Office of Economic Development and International Trade (OEDIT). The company’s first product, CereMetrix®, received FDA 510(k) clearance in March of 2018 (K173145).
The World Health Organization estimates that up to 1.2 billion people globally, nearly one in six of the world’s population, are afflicted by neurological and/or mental health disorders. Misdiagnosis rates range from 19-69%, and mental health dropout rate of 40% is primarily due to treatment ineffectiveness.
It takes an average of 10 years (and millions of dollars) to bring new brain health-related therapies to market, which is tied to flawed protocols, arduous/delayed data analysis, and avoidable amendments in clinical research.
CereHealth™ (parent company) is a state-of-the-art, web-based brain imaging and data analytics company with a proprietary, scalable artificial intelligence (AI) platform focused on multivariable analysis of quantitative biomarkers for central nervous system (CNS) disorders.
At Our Core
CereHealth™ focuses on removing diagnostic bias and applying innovation to create a more precise understanding of brain-based disorders, enabling healthcare providers to make more-informed decisions regarding patient-specific treatments, and contract research organizations (CROs) to access interlocked capabilities that add value to the clinical trial process and workflows.